Which of the following statements is true regarding the pathogenesis of lymphoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathogenesis of Lymphoma: Key Diagnostic and Clinical Features

Based on the evidence, bone marrow biopsy may be warranted in the diagnosis and staging of lymphoma.

Diagnostic Features of Lymphoma

  • The presence of Reed-Sternberg cells is a critical diagnostic feature for Hodgkin lymphoma, not something to be disregarded 1
  • Bone marrow biopsy is an essential component of lymphoma staging and diagnosis, particularly for detecting bone marrow infiltration which occurs in 3-18% of Hodgkin lymphoma cases and is more common in certain subtypes 1, 2
  • Excisional lymph node biopsy remains the gold standard for initial diagnosis of lymphoma, as fine-needle aspiration (FNA) or core needle biopsy alone is generally not suitable for primary diagnosis 3, 4
  • Immunophenotypic studies are crucial for accurate classification of many lymphoma subtypes, including peripheral T-cell lymphomas and diffuse large B-cell lymphomas 3

Clinical Manifestations and Presentation

  • Lymphoma patients commonly manifest intra-abdominal symptoms, contrary to the statement that they are unlikely to do so 5
  • Bowel obstruction can occur in lymphoma patients, particularly in those with gastrointestinal involvement 3
  • Lymphoma typically presents as painless adenopathy, with systemic symptoms (fever, unexplained weight loss, night sweats) occurring in more advanced disease stages 5
  • Submandibular lymph node enlargement is not pathognomonic for lymphoma and should not be the sole basis for diagnosis or exclusion; multiple conditions can cause lymphadenopathy in this region 3

Staging and Assessment

  • The Lugano Classification has modernized recommendations for evaluation, staging, and response assessment of both Hodgkin and non-Hodgkin lymphoma 6
  • FDG-PET/CT has been formally incorporated into standard staging for FDG-avid lymphomas 6
  • Bone marrow biopsy is warranted in lymphoma staging, though it may not be indicated for routine staging of all Hodgkin lymphoma and most diffuse large B-cell lymphomas with negative PET findings 6, 2
  • Progressive disease should be histologically documented to rule out transformation, especially if LDH levels are rising, a single site is growing disproportionately, extranodal disease develops, or new B symptoms appear 3

Epidemiology and Risk Factors

  • Non-Hodgkin lymphoma accounts for approximately 90% of all lymphomas, while Hodgkin lymphoma accounts for about 10% 7
  • Risk factors for lymphoma include family history, autoimmune diseases, HIV infection, HCV seropositivity, high body mass as a young adult, certain occupational exposures, and infectious diseases 6
  • Recent epidemiologic data suggest a worldwide increase in Non-Hodgkin lymphoma incidence (approximately 30% in 5 years prior to 2010) 6

Treatment Considerations

  • Treatment approaches differ between lymphoma subtypes, with non-Hodgkin lymphoma typically treated with regimens like R-CHOP, while Hodgkin lymphoma is treated with combined chemotherapy regimens such as ABVD 5
  • Chemotherapy toxicities include neuropathy, cardiotoxicity, and secondary cancers, which should be considered in treatment selection 5
  • Patients with lymphoma should receive appropriate vaccinations due to the immunosuppressive nature of the condition 5

In conclusion, bone marrow biopsy is indeed warranted in the diagnosis and staging of lymphoma, making option B the correct statement among the choices provided.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lymphoma: Diagnosis and Treatment.

American family physician, 2020

Guideline

Epidemiology of Lymphoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Lymphoma.

Primary care, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.